STEVEN BBUYE

Allopathic & Osteopathic Physicians|Emergency Medicine BROCKTON, MA NPI 1780943506

General Payments — all program years on this page

$130,772.88

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 51
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $40,676.29 across 14 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $40,645.0013
Travel and Lodging $31.291

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $40,676.2914

By program year

Program yearAmountRecords
2018 $134.221
2021 $488.872
2022 $52,681.2020
2023 $36,792.3014
2024 $40,676.2914

Records — PY2024 (14)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1137483394 Takeda Pharmaceuticals U.S.A., Inc. $3,320.00 01/17/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137483398 Takeda Pharmaceuticals U.S.A., Inc. $3,320.00 02/14/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137483401 Takeda Pharmaceuticals U.S.A., Inc. $3,320.00 03/11/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137483405 Takeda Pharmaceuticals U.S.A., Inc. $3,320.00 04/17/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137483409 Takeda Pharmaceuticals U.S.A., Inc. $805.00 05/06/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137483413 Takeda Pharmaceuticals U.S.A., Inc. $3,320.00 05/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137483417 Takeda Pharmaceuticals U.S.A., Inc. $31.29 05/20/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1137483420 Takeda Pharmaceuticals U.S.A., Inc. $3,320.00 06/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137483424 Takeda Pharmaceuticals U.S.A., Inc. $3,320.00 07/12/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137483428 Takeda Pharmaceuticals U.S.A., Inc. $3,320.00 08/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137483432 Takeda Pharmaceuticals U.S.A., Inc. $3,320.00 09/11/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137483435 Takeda Pharmaceuticals U.S.A., Inc. $3,320.00 10/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137483439 Takeda Pharmaceuticals U.S.A., Inc. $3,320.00 11/13/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137483443 Takeda Pharmaceuticals U.S.A., Inc. $3,320.00 12/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.